YESCARTA® (AXICABTAGENE CILOLEUCEL) RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY DLBCL AND MBCL, AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY

Lehdistötiedotteet   •   Elo 27, 2018 16:19 EEST

Gilead today announced that the European Commission (EC) has granted Marketing Authorization for Yescarta® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.

EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR GILEAD’S EPCLUSA®▼ (SOFOSBUVIR/VELPATASVIR) FOR THE TREATMENT OF ALL GENOTYPES OF CHRONIC HEPATITIS C

Lehdistötiedotteet   •   Heinä 11, 2016 08:54 EEST

The European Commission has granted marketing authorization for Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), the first pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

GILEAD PRESENTS FOLLOW-UP DATA FROM IDELALISIB (ZYDELIG®) REGISTRATIONAL STUDIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA, FOLLICULAR LYMPHOMA AND SMALL LYMPHOCYTIC LYMPHOMA

Lehdistötiedotteet   •   Joulu 13, 2014 16:23 EET

-- Results Describing Long-Term Safety and Disease Control Presented at the 56th American Society of Hematology Annual Meeting --

EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR GILEAD’S HARVONI®▼ (LEDIPASVIR/SOFOSBUVIR), THE FIRST SINGLE TABLET REGIMEN TO TREAT THE MAJORITY OF CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1 AND 4

Lehdistötiedotteet   •   Marras 19, 2014 08:49 EET

-- Once Daily Single Tablet Regimen Eliminates the Need for Interferon and Ribavirin for Patients with Genotype 1 and 4 Hepatitis C without Cirrhosis or with Compensated Cirrhosis -- -- Combination of Harvoni and Ribavirin Offers New Interferon-Free Treatment for Genotype 3 Patients with Cirrhosis and/or Prior Treatment Failure --

European Commission Grants Marketing Authorization for Gilead’s Zydelig (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

Lehdistötiedotteet   •   Syys 29, 2014 08:44 EEST

The European Commission has granted marketing authorization for Zydelig®(idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers – chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).

Kuvat & videot 2 kuvaa

Yhteyshenkilöt 2 yhteyshenkilöä

  • Lehdistökontakti
  • Medical Director, Nordics
  • anhvetidtehy.hezomivmehxlgnzaayhrdoz@gtqildheaund.okcoxamsh
  • +4553807882
  • +46(0)850571800

  • Lehdistökontakti
  • General Manager, Nordics
  • mulbhiuaedmodivxneri.metakahkomeukct@gihilgmeaqbd.uwcoiamwa
  • +46(0)850571808
  • +46(0)850571800

Gilead Sciences

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific. The Nordic Organization started up 2008, and the head office is based in Stockholm, Sweden.

Osoite

  • Gilead Sciences
  • Rajatorpantie 41 C
  • 01640 Vantaa
  • Suomi